Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key ...

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin ...

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup ...

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s ...

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of ...

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical ...